Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease
Open Access
- 2 December 2009
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 31 (1), 20-34
- https://doi.org/10.1111/j.1365-2036.2009.04112.x
Abstract
Background Anti‐Tumour necrosis factor (TNF) therapy is now well established in the treatment of inflammatory bowel disease and the risk of opportunistic infection is recognized. However, specific considerations regarding screening, detection, prevention and treatment of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease are not widely adopted in practice. Aim To provide a detailed and comprehensive review of the relevance of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease. Methods Literature search was conducted using Medline, Pubmed and Embase using the terms viral infection, hepatitis, herpes, CMV, EBV, HPV, anti‐TNF, infliximab, adalimumab, certolizumab pegol and etanercept. Hepatitis B and C and HIV had the largest literature associated and these have been summarized in Tables. Results Particular risks are associated with the use of anti‐TNF drugs in patients with hepatitis B infection, in whom reactivation is common unless anti‐viral prophylaxis is used. Reactivation of herpes zoster is the most common viral problem associated with anti‐TNF treatment, and may be particularly severe. Primary varicella infection may present with atypical features in patients on anti‐TNF. Conclusion Appreciation of risks of chronic viral disease associated with anti‐TNF therapy may permit early recognition, prophylaxis and treatment.Keywords
This publication has 102 references indexed in Scilit:
- Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseasesAutoimmunity Reviews, 2008
- Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reportsClinical Rheumatology, 2008
- From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasisJournal of the American Academy of Dermatology, 2008
- Safe and effective application of anti-TNF- in a patient infected with HIV and concomitant Crohn's diseaseGut, 2006
- Etanercept therapy in two patients with psoriasis and concomitant hepatitis CJournal of the American Academy of Dermatology, 2006
- Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infectionJournal of the American Academy of Dermatology, 2006
- Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled studyJournal of Hepatology, 2004
- Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 casesJournal of the American Academy of Dermatology, 2004
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- Tumor necrosis factor enhances replication of human immunodeficiency virus (HIV) in vitroBiochemical and Biophysical Research Communications, 1989